Calciphylaxis: A still unmet challenge

Journal of Nephrology

Volumn 24, Issue 2, 2011, Pages 142-148

  Brandenburg, Vincent M ^a   Cozzolino, Mario ^b   Ketteler, Markus ^c  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b UNIVERSITY OF MILAN   (Italy)

^c KLINIKUM COBURG   (Germany)

Author keywords

Calcific uremic arteriolopathy; Calcification; Calciphylaxis; Chronic kidney disease; Vascular disease

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; BISPHOSPHONIC ACID DERIVATIVE; CINACALCET; HEPARIN; MINERAL; OSTEOCALCIN; SODIUM THIOSULFATE; STEROID; VITAMIN K GROUP; WARFARIN;

ARTERY CALCIFICATION; ARTICLE; BONE DISEASE; CALCINOSIS; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; DIALYSIS; DISEASE CONTROL; DISEASE COURSE; DISEASE SEVERITY; HUMAN; HYPERBARIC OXYGEN; PARATHYROIDECTOMY; PATHOPHYSIOLOGY; RISK ASSESSMENT; RISK FACTOR; SURGICAL WOUND; WOUND CARE;

ARTERIOLES; CALCINOSIS; CALCIPHYLAXIS; CHELATING AGENTS; CHRONIC DISEASE; HUMANS; KIDNEY DISEASES; SKIN; THIOSULFATES;

EID: 79953691104     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/JN.2011.6366     Document Type: Article

References (33)

1. Selye H, Grasso G, Dieudonne J. On the role of adjuvants in calciphylaxis. Rev Allergy. 1961;15:461-465.
2. Hafner J, Keusch G, Wahl C, Sauter B, F et al. Uremic smallartery disease with medial calcification and intimal hyperplasia (so-called calciphylaxis): a complication of chronic renal failure and benefit from parathyroidectomy. J Am Acad Dermatol. 1995;33:954-962.
3. Gipstein RM, Coburn JW, Adams DA, et al. Calciphylaxis in man: a syndrome of tissue necrosis and vascular calcification in 11 patients with chronic renal failure. Arch Intern Med. 1976;136:1273-1280.
4. Angelis M, Wong LL, Myers SA, Wong LM. Calciphylaxis in patients on hemodialysis: a prevalence study. Surgery. 1997;122:1083-1089.
5. Mazhar AR, Johnson RJ, Gillen D, et al. Risk factors and mortality associated with calciphylaxis in end-stage renal disease. Kidney Int. 2001;60:324-332.
6. Weenig RH. Pathogenesis of calciphylaxis: Hans Selye to nuclear factor kappa-B. J Am Acad Dermatol. 2008;58:458-471.
7. Franks AG Jr. Skin manifestations of internal disease. Med Clin North Am. 2009;93:1265-1282.
8. Fine A, Zacharias J. Calciphylaxis is usually non-ulcerating: risk factors, outcome and therapy. Kidney Int. 2002;61:2210-2217.
9. Rogers NM, Coates PT. Calcific uraemic arteriolopathy: an update. Curr Opin Nephrol Hypertens. 2008;17:629-634.
10. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 31-2001. A 70-year-old woman with end-stage renal disease and cutaneous ulcers. N Engl J Med. 2001;345:1119-1124.
11. Meissner M, Gille J, Kaufmann R. Calciphylaxis: no therapeutic concepts for a poorly understood syndrome? J Dtsch Dermatol Ges. 2006;4:1037-1044.
12. Au S, Crawford RI. Three-dimensional analysis of a calciphylaxis plaque: clues to pathogenesis. J Am Acad Dermatol. 2002;47:53-57.
13. Janigan DT, Hirsch DJ, Klassen GA, MacDonald AS. Calcified subcutaneous arterioles with infarcts of the subcutis and skin ("calciphylaxis") in chronic renal failure. Am J Kidney Dis. 2000;35:588-597.
14. Nigwekar SU, Wolf M, Sterns RH, Hix JK. Calciphylaxis from nonuremic causes: a systematic review. Clin J Am Soc Nephrol. 2008;3:1139-1143.
15. Coen G, De Paolis P, Ballanti P, et al. Peripheral artery calcifications evaluated by histology correlate to those detected by CT: relationships with fetuin-A and FGF-23. J Nephrol. 2010 Oct 14. [Epub ahead of print].
16. Mathur RV, Shortland JR, El Nahas AM. Calciphylaxis. Postgrad Med J. 2001;77:557-561.
17. Budisavljevic MN, Cheek D, Ploth DW. Calciphylaxis in chronic renal failure. J Am Soc Nephrol. 1996;7:978-982.
18. Weenig RH, Sewell LD, Davis MD, et al. Calciphylaxis: natural history, risk factor analysis, and outcome. J Am Acad Dermatol. 2007;56:569-579.
19. Brandenburg VM, Floege J, Ketteler M. Kalzifizierende urämische Arteriolopathie. Nephrologie. 2009;4:65-66.
20. Krueger T, Westenfeld R, Schurgers L, Brandenburg V. Coagulation meets calcification: the vitamin K system. Int J Artif Organs. 2009;32:67-74.
21. Jahnen-Dechent W, Schafer C, Ketteler M, et al. Mineral chaperones: a role for fetuin-A and osteopontin in the inhibition and regression of pathologic calcification. J Mol Med. 2008;86:379-389.
22. Cranenburg EC, Vermeer C, Koos R, et al. The circulating inactive form of matrix Gla protein (ucMGP) as a biomarker for cardiovascular calcification. J Vasc Res. 2008;45:427-436.
23. Schafer C, Heiss A, Schwarz A, et al. The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest. 2003;112:357-366.
24. Fine A, Fontaine B. Calciphylaxis: the beginning of the end? Perit Dial Int. 2008;28:268-270.
25. Girotto JA, Harmon JW, Ratner LE, et al. Parathyroidectomy promotes wound healing and prolongs survival in patients with calciphylaxis from secondary hyperparathyroidism. Surgery. 2001;130:645-650.
26. Mawad HW, Sawaya BP, Sarin R, et al. Calcific uremic arteriolopathy in association with low turnover uremic bone disease. Clin Nephrol. 1999;52:160-166.
27. Negri AL. Phosphate binders, cardiovascular calcifications and mortality: do we need another survival study with sevelamer? J Nephrol. 2010;23:653-657.
28. Cozzolino M, Mazzaferro S, Brandenburg V. The treatment of hyperphosphataemia in CKD: calcium-based or calcium-free phosphate binders? Nephrol Dial Transplant. 2011;26:402-407.
29. Cozzolino M, Brandenburg V. Warfarin: to use or not to use in chronic kidney disease patients? J Nephrol. 2010;23:648-652.
30. Coates T, Kirkland GS, Dymock RB, et al. Cutaneous necrosis from calcific uremic arteriolopathy. Am J Kidney Dis. 1998;32:384-391.
31. Rogers NM, Chang SH, Teubner DJ, Coates PT. Hyperbaric oxygen as effective adjuvant therapy in the treatmentof distal calcific uraemic arteriolopathy. Nephrol Dial Transplant. 2008;1:244-249.
32. Schlieper G, Brandenburg V, Ketteler M, Floege J. Sodium thiosulfate in the treatment of calcific uremic arteriolopathy. Nat Rev Nephrol. 2009;5:539-543.
33. Raymond CB, Wazny LD. Sodium thiosulfate, bisphosphonates, and cinacalcet for treatment of calciphylaxis. Am J Health Syst Pharm. 2008;65:1419-1429.